ProMIS Neurosciences Inc. (NASDAQ:PMN)
| Market Cap | 81.47M-36.0% |
| Revenue (ttm) | 0 |
| Net Income | -42.23M-401.1% |
| EPS | -16.89-243.3% |
| Shares Out | 8.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,007 |
| Open | 9.02 |
| Previous Close | 9.12 |
| Day's Range | 8.92 - 9.45 |
| 52-Week Range | 6.27 - 27.40 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 31.00(+241.22%) |
| Earnings Date | Nov 11, 2026 |
ProMIS Neurosciences Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About PMN
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PMN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PMN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PMN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PMN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PMN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| PMN310 development program costs | $7.79M | 69.27% |
| Employee costs | $2.92M | 25.95% |
| Other income | $536.74K | 4.78% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PMN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PMN from public contracts
Source: USAspending.gov
PMN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PMN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score